Skip to main content

FDA Approves Tbo-Filgrastim for Neutropenia



August 29, 2012 — The US Food and Drug Administration (FDA) has approved tbo-filgrastim (Sicor Biotech/Teva Pharmaceuticals) for the treatment of severe neutropenia associated with use of chemotherapy in nonmyeloid malignancies.
Filgrastim is a granulocyte colony-stimulating factor (G-CSF) analog used to stimulate the proliferation and differentiation of granulocytes. Two forms of filgrastim are already available in the US — one injected daily (Neupogen, Amgen) and a pegylated form injected once per chemotherapy cycle (Neulasta, Amgen); another version of filgrastim (Tevagrastim, Teva) has been marketed outside of the US. Teva notes that Tevagrastim and Neupogen are biosimilar, and that the Neupogen patent will expire in the US next year. The company also notes that that tbo-filgrastim is a short-acting recombinant form of G-CSF, and that it is the first new G-CSF to be approved in the US in more than 10 years. Teva reports that it will start marketing tbo-filgrastim possibly as early as November 2013, in accordance with the settlement it reached with Amgen.
Approval of tbo-filgrastim was based on the findings of a clinical study of 348 adult patients with advanced breast cancer receiving treatment with the anticancer drugs doxorubicin and docetaxel. Patients were randomly assigned to receive tbo-filgrastim, a placebo, or a filgrastim product not available in the US.
Patients receiving tbo-filgrastim recovered from severe neutropenia in 1.1 days compared with 3.8 days in those receiving the placebo.
Adverse events associated with tbo-filgrastim were evaluated in 3 clinical studies including 680 adults with breast cancer, lung cancer, or non-Hodgkin's lymphoma receiving high-dose myeloablative chemotherapy. The most common side effect observed in those receiving tbo-filgrastim was bone pain.

Comments

Post a Comment

Popular posts from this blog

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more